Literature DB >> 10477047

Synergistic anorectic effect of dehydroepiandrosterone and d-Fenfluramine on the obese Zucker rat.

G Gillen1, J R Porter, F Svec.   

Abstract

Fasted obese, female Zucker rats accustomed to eating a single high fat meal within 1 h a day were treated with intraperitoneal injections of dehydroepiandrosterone (DHEA) and dextrofenfluramine (d-fen), either individually or in combination. Caloric intake was measured over a 1-h period 2 h after drug administration, and results compared to that of vehicle-treated controls. At 50 mg/kg body weight, DHEA did not affect food intake. At doses of < or = 2 mg/kg d-fen did not affect food intake. Together, however, DHEA 50 mg/kg and d-fen < or = 2 mg/kg significantly decreased food intake. At doses of > or = 3 mg/kg d-fen diminished caloric intake by itself, and the addition of DHEA significantly augmented this effect. Neurotransmitter levels in select regions of the hypothalamus of animals treated using a similar drug protocol showed several changes in the levels of serotonin and its metabolite 5 hydroxyindole acetic acid (5-HIAA). It is hypothesized that DHEA augments the production of serotonin while d-fenfluramine enhances its release, and together these two actions may account for the synergistic action of DHEA and d-fenfluramine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477047     DOI: 10.1016/s0031-9384(99)00057-8

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  2 in total

1.  Dehydroepiandrosterone regulates insulin-like growth factor-1 system in adult rat hypothalamus.

Authors:  Maria Flavia Ribeiro; Luis Miguel Garcia-Segura
Journal:  Endocrine       Date:  2002-03       Impact factor: 3.925

2.  Associations of lifestyle factors with serum dehydroepiandrosterone sulphate and insulin-like growth factor-1 concentration in prepubertal children.

Authors:  Aino Mäntyselkä; Jarmo Jääskeläinen; Aino-Maija Eloranta; Juuso Väistö; Raimo Voutilainen; Ken Ong; Søren Brage; Timo A Lakka; Virpi Lindi
Journal:  Clin Endocrinol (Oxf)       Date:  2017-11-29       Impact factor: 3.478

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.